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Background. Group B Streptococcus (GBS) remains a leading cause of neonatal sepsis in high-income contexts, despite declines 
due to intrapartum antibiotic prophylaxis (IAP). Recent evidence suggests higher incidence in Africa, where IAP is rare. We investi-
gated the global incidence of infant invasive GBS disease and the associated serotypes, updating previous estimates.
Methods. We conducted systematic literature reviews (PubMed/Medline, Embase, Latin American and Caribbean Health 
Sciences Literature [LILACS], World Health Organization Library Information System [WHOLIS], and Scopus) and sought unpub-
lished data regarding invasive GBS disease in infants aged 0–89 days. We conducted random-effects meta-analyses of incidence, case 
fatality risk (CFR), and serotype prevalence.
Results. We identified 135 studies with data on incidence (n = 90), CFR (n = 64), or serotype (n = 45). The pooled incidence of 
invasive GBS disease in infants was 0.49 per 1000 live births (95% confidence interval [CI], .43–.56), and was highest in Africa (1.12) 
and lowest in Asia (0.30). Early-onset disease incidence was 0.41 (95% CI, .36–.47); late-onset disease incidence was 0.26 (95% CI, 
.21–.30). CFR was 8.4% (95% CI, 6.6%–10.2%). Serotype III (61.5%) dominated, with 97% of cases caused by serotypes Ia, Ib, II, III, 
and V.
Conclusions. The incidence of infant GBS disease remains high in some regions, particularly Africa. We likely underestimated 
incidence in some contexts, due to limitations in case ascertainment and specimen collection and processing. Burden in Asia requires 
further investigation.
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Group B Streptococcus (GBS; Streptococcus agalactiae) is a 
leading infectious cause of neonatal morbidity and mortal-
ity, well described in high-income contexts (HICs) [1–8], 
but less well studied in low- to middle-income contexts 
(LMICs) and low-income contexts (LICs) [9]. A  systematic 
review in 2012 [9], reported an overall incidence of invasive 
GBS disease among infants of 0.53 per 1000 live births (95% 
confidence interval [CI], .41–.62), with the highest incidence 
in Africa (1.21 per 1000 live births), followed by the Americas 
(0.67 per 1000 live births) and the lowest incidence in the 
Western Pacific (0.15 per 1000 live births) and Southeast Asia 
(0.016 per 1000 live births). Although data, especially from 
LICs, were limited, case fatality risks (CFRs) were higher in 
Africa (22%) compared with the Americas (11%) or Europe 
(7%) [9].
Understanding the global burden of GBS disease in young 
infants (0–89 days), including neonates (0–27 days), is impor-
tant to guide public health decision making on interventions. 
Many HICs have implemented intrapartum antibiotic prophy-
laxis (IAP), aiming to reduce early-onset GBS disease (EOGBS; 
days 0–6) for women with rectovaginal GBS colonization 
detected through microbiological screening or with clinical risk 
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factors [10, 11]. However, this strategy will not reduce late-on-
set infant GBS disease (LOGBS; onset on days 7–89 of life), and 
in LMICs and LICs, where there are more home deliveries and 
women present later for delivery, IAP may be less feasible and 
effective than other potential strategies for prevention, such as a 
maternal GBS vaccine.
This article therefore aims to examine the incidence of inva-
sive GBS disease among young infants and the associated CFR 
and serotypes causing GBS invasive disease (Figure 1). It is part 
of a supplement estimating the burden of GBS disease among 
pregnant women, stillbirths, and infants [12]. The supplement 
includes systematic reviews and meta-analyses on GBS colo-
nization, and adverse outcomes associated with GBS around 
birth [10, 13–19], which provide data inputs for estimating the 
worldwide burden of GBS [20].
OBJECTIVES
1. To provide a comprehensive, systematic literature review and 
meta-analyses on the burden of infant invasive GBS disease 
to include:
a. Incidence of infant GBS disease: overall incidence risk, 
including stratification by EOGBS and LOGBS.
b. CFR for EOGBS and LOGBS (7–89  days) and neonatal 
disease (7–27 days).
c. Serotype distribution: prevalence of GBS serotypes caus-
ing GBS disease among infants.
2. To generate parameters to be used as data inputs in a com-
partmental model estimating the burden of GBS in preg-
nancy for women, stillbirth, and infants; including
a. EOGBS to LOGBS ratio.
b. Clinical syndrome (proportion of neonatal disease that 
was meningitis or sepsis).
3. To evaluate data gaps and recommend improvements for the 
data regarding GBS disease in young infants.
METHODS
This article is part of a protocol entitled “Systematic estimates of the 
global burden of GBS in pregnant women, stillbirths and infants,” 
submitted for ethical approval to the London School of Hygiene 
& Tropical Medicine (reference number 11966) and approved on 
30 November 2016. The general methods are described elsewhere 
[12]; here we present details specific to estimates related to the 
incidence of invasive GBS disease among infants.
We included studies that described incidence risk, deaths, 
or serotypes of bacterial isolates among infants aged 0–89 days 
with invasive GBS disease. Eligible studies were those report-
ing data published or unpublished between 1 January 2000 
and 31 January 2017, limited to humans and with no language 
Figure 1. Infant group B streptococcal (GBS) disease in disease schema for GBS, as described by Lawn et al [12].
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restrictions. We identified data through systematic review of 
the published literature and through an investigator group that 
sought unpublished data from clinicians, researchers, and rele-
vant professional institutions worldwide.
Definitions
Invasive GBS disease was defined as laboratory isolation of 
S. agalactiae from any normally sterile site using conventional 
microbiological methods together with any signs of clinical dis-
ease. EOGBS was defined as invasive GBS disease in infants aged 
0–6 days after birth and LOGBS in infants 7–89 days after birth. 
Incidence risk was defined as cases per 1000 live births and CFR 
as number of deaths in GBS cases divided by total GBS cases.
Search Strategy
We undertook systematic literature searches of PubMed/
Medline, Embase, Literature in the Health Sciences in Latin 
America and the Caribbean (LILACS), the World Health 
Organization Library Information System (WHOLIS), and 
Scopus databases using the search terms (“Streptococcus aga-
lactiae” [Medical subject headings (MeSH)] OR “Streptococcus 
Group B” OR “Group B streptococcal”) AND “infant,” “out-
come,” “death,” “mortality,” “case AND fatality AND rate.” We 
limited searches to humans and publications from 1 January 
2000 to 31 January 2017 (see Supplementary Table 1 for the full 
list of search terms). For consistency, we used the same search 
terms as a previous systematic review [9]. We did not apply date 
or language restrictions; texts were translated to English when 
published in other languages. An additional search for reports 
with serotype data was performed, using the search terms 
(“Streptococcus agalactiae serotype” [MeSH] OR “Streptococcus 
Group B serotype” OR “Group B streptococcal serotype”) using 
the same limits above. We used snowball searches of article ref-
erence lists including reviews to identify additional studies
One investigator performed the database search, screened for 
duplicates, and screened titles and abstracts to assess eligibility 
for inclusion. Two independent investigators (L. M. and M. K. 
L.) assessed the full-length articles associated with selected 
abstracts to confirm eligibility and extract data. Where there 
was discrepancy between the 2 reviewers, a third investigator 
(A. S.) made the final decision.
Study Selection
We included studies with original data on GBS disease in 
infants who were aged 0–89 days at onset of infection episode, 
with clinical specimens obtained from a sterile site, which had 
a population denominator (total live births). We excluded 
studies focusing on very high-risk groups (such as only human 
immunodeficiency virus [HIV]–infected infants or only pre-
term infants), where data were not representative of live births 
in the population. Where countries had multiple or duplicated 
publications or systematically collected surveillance data, we 
included the most recent data. Studies reporting GBS disease 
in infants aged 0–90 days that did not specify age at onset for 
the individual cases were included with the 0–89 day studies as 
the probability of a case on day 90 is negligible. For full details 
of inclusion and exclusion criteria, see Supplementary Table 2.
Data Abstraction
We used a standardized data abstraction tool to capture infor-
mation on the study design (prospective or retrospective), set-
ting (health facility or not), use of IAP, timing of clinical disease 
(onset in the first 24–48 hours, EOGBS, and LOGBS), outcomes 
(survived or died), sample type (cerebrospinal fluid, blood, or 
other sterile site) and GBS serotype. For facility-based studies 
limited to babies born at the facility, facility live births was used 
as denominator. Where studies included inborn and outborn 
babies, a population denominator of all live births in the catch-
ment area of the health facility was used. Data on study location 
were also abstracted including country and town. These data 
were imported into Stata version 14 software.
Analysis
We used random-effects meta-analyses to estimate overall infant 
disease incidence, EOGBS and LOGBS incidence, the EOGBS 
to LOGBS incidence ratio, and CFRs using the DerSimonian 
and Laird method [21]. In addition to worldwide estimates, 
estimates by United Nations regions and/or subregions were 
obtained when sufficient data were available.
To assess bias, we performed the following sensitivity 
analyses:
1. Invasive disease:
a. Infant invasive disease limited to facility-based studies 
where denominator was facility births.
b. EOGBS estimates limited to studies including data for 
days 0–6 after birth.
c. LOGBS estimates limited to studies including data for 
days 7–89 after birth.
d. Late-onset neonatal incidence limited to studies with data 
for days 7–27 after birth.
2. The ratio of early-onset disease to late-onset disease, includ-
ing only studies considered to be less subject to case finding 
bias resulting from low access to care, nonsystematic sam-
pling, or suboptimal laboratory detection methods [22–25] 
as considered by the expert advisory group.
RESULTS
Literature Search and Study Selection
We identified 7535 articles for consideration from database 
searches, 318 additional records from expert groups in neona-
tal care and reference lists, and 7 datasets from an investigator 
group [22, 23, 26] (Araujo da Silva et al. unpublished, Dhaded et 
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al. unpublished, Saha et al. unpublished, Sigaúque et al. unpub-
lished). One hundred thirty-five articles (reporting data from 57 
countries) met our inclusion criteria (search strategy of study 
selection in Figure 2). Of these, 90 reported incidence [22–96], 
(EOGBS: 74 studies; LOGBS: 33 studies), 64 reported CFR [22–
27, 30, 34, 37, 38, 41–43, 46, 49–57, 59, 61, 63, 68, 70, 71, 73–75, 
78–81, 84, 89, 90, 92, 95–111], and 45 reported serotype data 
[22–25, 31, 42, 47, 50, 55, 61, 63, 66, 70, 73, 78, 81, 84, 112–138]. 
(The full list of articles included in this review is available in 
Supplementary Table 3.) Articles excluded because more recent 
data from the same population were available are shown in 
Supplementary Table 4 and Supplementary Figure 1. Compared 
to the previously published global GBS invasive disease estimates 
[9], we included 61 additional studies: 34 reporting incidence, 35 
CFR, and 26 serotype (Supplementary Figure 2).
Study Characteristics
There were more data from HICs (77 studies) compared 
to LMICs (18 studies), of which 12 were from Africa (11 in 
sub-Saharan Africa, 1 in North Africa). Data inputs are illus-
trated in Figure 3A and 3B. Data inputs of the previous systematic 
review [9] are shown in Supplementary Figures 3A and 3B. Most 
studies (109/135) were facility based and information about IAP 
use was available from 116 of 135 studies (Table 1). Seventy-six 
studies reported any use of IAP: 27 of 76 (35.5%) were based on 
screening, 14 of 76 (18.4%) were based on a risk factor algorithm, 
and 35 of 76 (46.1%) did not specify a strategy. Of those studies 
reporting incidence, 58 of 90 (64.4%) reported use of any IAP; this 
was highest in developed countries (46/58 [79.3%]) and lowest in 
sub-Saharan Africa (3/11 [27.3%]) (Supplementary Figure 4). Of 
74 studies that reported EOGBS, 49 (67.1%) reported IAP use 
and approximately one-third of articles (24/74 [32.4%], includ-
ing 6 studies from LICs and LMICs) reported information about 
age at onset of EOGBS. Serotype was available in studies from 25 
countries (developed countries, 16; Central and South America, 
4; Southern and Eastern Africa, 3; Eastern Asia, 2). We were una-
ble to abstract data on laboratory methods used, maternal risk 
factors, and weight or gestational age at birth of neonates.
Figure 2. Search strategy and process of study selection. Abbreviation: GBS, group B Streptococcus.
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Incidence Risk of Group B Streptococcus Disease
There were 6199 infants with invasive GBS disease among 
13 300 000 live births in 53 countries. The incidence risk (per 
1000 live births) for infant GBS disease was 0.49 (95% CI, .43–
.56) overall, being 1.12 in Africa, 0.49 in Latin America and the 
Caribbean, 0.46 in developed countries, and the lowest in Asia, 
0.30. Incidence was highest in Southern Africa (2.00 [95% CI, 
.74–3.26]) and lowest in Southeast Asia (0.21 [95% CI, .09–.32]; 
meta-analysis in Figure  4). There were 3664 cases of EOGBS 
from 9 866 793 live births. Incidence risk (per 1000 live births) 
of EOGBS worldwide was 0.41 (95% CI, .36–.47) and ranged 
from 0.32 (95% CI, .22–.41) in Asia to 0.71 (95% CI, .24–1.18) in 
Africa. The Caribbean had the highest incidence risk of EOGBS 
(1.47), followed by Southern Africa (1.07) and South Asia the 
lowest (0.20) (Supplementary Figure 5). Among EOGBS cases, 
68% (95% CI, 57%–79%) developed symptoms in the 24 hours 
after birth, being higher in HIC (74% [95% CI, 58%–89%]) 
compared with LICs (31% [95% CI, –20% and 82%]); meta-anal-
ysis included as Supplementary Figure 6). There were 2003 cases 
of LOGBS among 8 975 899 live births. Incidence risk of LOGBS 
worldwide was 0.26 (95% CI, .21–.30), ranging from 0.04 (95% CI, 
–.02 to .09) in Asia to 0.65 (95% CI, .25–1.05) in Africa. Southern 
Africa had the highest incidence risk of LOGBS (0.93), and South 
America, Western Africa, and Southeastern Asia had the lowest 
(0.0, 0.0, and 0.03, respectively, based on the single study cap-
tured from each of these regions; Supplementary Figure 7).
Case Fatality Risk
There were 570 deaths among 6501 infant cases. The overall CFR 
was 8.4% (95% CI, 6.6%–10.2%). CFR in Africa (18.9% [95% CI, 
13.7%–24.0%]) was 4 times higher than in developed countries 
(4.7% [95% CI, 3.3%–6.1%]) (meta-analysis in Supplementary 
Figure 8). EOGBS CFR was 10.0% (95% CI, 7.0%–12.0%) rang-
ing from 5.0% (95% CI, 4.0%–7.0%) in developed countries to 
Figure 3. Worldwide distribution of data inputs. A, Map illustrating number of studies by country reporting incidence of group B streptococcal (GBS) invasive disease. B, 
Map illustrating overall incidence of GBS disease among infants by country included in the meta-analyses. Borders of countries/territories in map do not imply any political 
statement.
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27.0% (95% CI, 17.0%–37.0%) in Africa. LOGBS CFR was 7.0% 
(95% CI, 4.0%–9.0%) and, consistently with overall and EOGBS 
CFR, was lowest in developed countries (4.0% [95% CI, 3.0%–
6.0%]) and highest in Africa (12.0% [95% CI, 5.0%–19.0%]) 
(meta-analysis in Supplementary Figures 9 and 10, respectively).
Serotype Distribution
A total of 6500 bacterial isolates were included in the meta-anal-
ysis of serotype prevalence (data inputs are illustrated in 
Supplementary Figure 11). Five serotypes (Ia, Ib, II, III, and V) 
accounted for 97% of invasive isolates in all regions with serotype 
data (Figure  5). Serotype III was the most prevalent serotype 
across the United Nations subregions, although it was lower in 
South America (34%) compared with other subregions. Nearly 
half (47%) of EOGBS cases and 73.0% of LOGBS cases were 
caused by serotype III. Serotype Ia, Ib, and V were frequently 
isolated in EOGBS (22.8%, 8.0%, and 10.6%, respectively) and 
LOGBS (14.2%, 5.3%, and 4.0%) (Supplementary Figure 12).
Early-Onset to Late-Onset Group B Streptococcus Disease Ratio
The overall ratio of EOGBS to LOGBS disease was 1.72 (95% 
CI, 1.35–2.21). The highest ratio was in Asia (5.99 [95% CI, 
Table 1. Characteristics of Included Studies Investigating Invasive Group B Streptococcal Disease in Infants
Characteristic Total (135 Articles) Incidence (90 Articles) CFR (64 Articles) Serotypes (47 Articles)
United Nations subregion
 Developed countries 58 (43.0) 32 (35.6) 28 (43.8) 32 (68.1)
 Central America 2 (1.5) 2 (2.2) 1 (1.6) 1 (2.1)
 Caribbean 6 (4.4) 5 (5.6) 4 (6.2) 0 (0.0)
 South America 15 (11.1) 9 (10.0) 8 (12.5) 4 (8.5)
 Northern Africa 1 (0.7) 1 (1.1) 0 (0.0) 0 (0.0)
 Eastern Africa 5 (3.7) 4 (4.4) 4 (6.2) 2 (4.3)
 Western Africa 3 (2.2) 3 (3.4) 1 (1.6) 0 (0.0)
 Southern Africa 3 (2.2) 3 (2.3) 3 (4.7) 2 (4.3)
 Eastern Asia 17 (12.6) 7 (7.8) 8 (12.5) 5 (10.6)
 Western Asia 8 (5.9) 7 (7.8) 2 (3.1) 0 (0.0)
 Southern Asia 7 (5.2) 7 (7.8) 3 (4.7) 1 (2.1)
 Southeastern Asia 10 (7.4) 10 (11.1) 2 (3.1) 0 (0.0)
Study design
 Prospective 53 (39.3) 46 (51.1) 26 (40.6) 12 (25.5)
 Retrospective 82 (60.7) 44 (48.9) 38 (59.3) 35 (74.5)
Population/facility-based studya
 Population-based 24 (18.8) 18 (20.0) 13 (20.3) 35 (76.1)
 Facility based 109 (81.2) 71 (78.9) 50 (78.1) 11 (23.9)
Reporting period
 Full period (0–89 d)b 10 (7.4) 10 (11.1) 10 (15.6) 6 (12.7)
 Full EOGBS period (0–6 d)c 42 (31.1) 42 (46.7) 30 (46.9) 13 (27.7)
 Full LOGBS period (7–89 d)d 11 (8.1) 11 (12.2) 11 (17.2) 5 (10.6)
Specimen type
 Blood only 27 (20.0) 19 (21.8) 12 (18.8) 3 (6.4)
 CSF only 5 (3.7) 2 (2.3) 2 (3.1) 2 (4.3)
 Blood and CSF 75 (55.6) 53 (58.9) 36 (56.3) 27 (57.5)
 All sterile sites 25 (18.5) 14 (15.6) 14 (21.9) 15 (31.9)
IAP
 Any IAP used 76 (65.5) 58 (69.9) 41 (70.7) 21 (43.8)
 No IAP 40 (34.5)  25 (30.1) 17 (29.3) 27 (56.2)
Rural/urban
 Rural 2 (1.5) 2 (2.2) 1 (1.6) 1 (2.1)
 Urban 69 (51.1) 46 (51.1) 33 (51.6) 21 (44.7)
 Semirural 2 (1.5) 2 (2.2) 2 (3.1) 2 (4.3)
 Mixed 30 (22.2) 22 (24.4) 15 (23.4) 11 (23.4)
 Not described 32 (23.7) 18 (20.0) 13 (20.3) 12 (25.5)
Data are presented as No. (%).
Abbreviations: CFR, case fatality risk; CSF, cerebrospinal fluid; EOGBS, early-onset group B Streptococcus; IAP, intrapartum antibiotic prophylaxis; LOGBS, late-onset group B Streptococcus.
aTwo missing values for population/facility-based and 19 missing values for IAP use.
bStudies reporting incidence among infants for the whole period aged 0-89 days among all studies.
cStudies reporting EOGBS cases among infants for the whole period aged (0-6 days) among studies reporting EOGBS in each category.
dStudies reporting LOGBS cases among infants for the whole period (7–89 days) among studies reporting EOGBS in each category.
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Figure 4. Pooled estimated incidence risk per 1000 live births of overall infant invasive group B streptococcal disease. Abbreviations: CI, confidence interval; ES, effect 
size; GBS, group B Streptococcus.
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2.40–14.92]) and lowest in Africa (1.02 [95% CI, .82–1.28]). The 
ratio in developed countries was similar to the overall ratio, at 1.82 
(95% CI, 1.29–2.57) (meta-analysis as Supplementary Figure 13).
Clinical Syndrome (Sepsis or Meningitis)
Twenty-three percent of all GBS invasive cases (95% CI, 14%–
32%) were meningitis. Among EOGBS cases, 78% (95% CI, 
67%–88%) had sepsis and 16% (95% CI, 8%–25%) had menin-
gitis (meta-analysis of meningitis cases among EOGBS cases in 
Supplementary Figure 14). The meningitis/sepsis ratio was 0.18 
(95% CI, .13–.25). Among LOGBS cases, there was a lower per-
centage of sepsis; 53% (95% CI, 43%–62%) had sepsis and 43% 
(95% CI, 34%–51%) had meningitis (meta-analysis of meningi-
tis cases among LOGBS cases in Supplementary Figure 15). The 
meningitis:sepsis ratio was 0.78 (95% CI, .55–1.10).
Sensitivity Analyses to Assess Bias
Among facility-based studies with facility births denominator 
(n  =  71), the incidence among infants 0–89  days of age was 
slightly higher than the main analysis (0.53 [95% CI, .44–.61]). 
The highest incidence was in Southern Africa (2.00 [95% CI, 
.73–3.26]) and the lowest in Southeastern Asia (0.21 [95% CI, 
.09–.32]) (Supplementary Figure  16). EOGBS incidence was 
0.43 (95% CI, .35–.50) per 1000 live births (Supplementary 
Figure  17) and LOGBS incidence was 0.31 (95% CI, .24–.38) 
per 1000 live births (Supplementary Figure 18).
When we limited estimates of EOGBS to studies with 
reported data for days 0–6 of life (42/74 studies with EOGBS 
data reported), EOGBS incidence (0.42 [95% CI, .35–.49]) was 
similar to the main analysis (meta-analyses in Supplementary 
Figure 19).
Figure 5. Global distribution of group B Streptococcus (GBS) serotypes in invasive disease in young infants (N = 6500 isolates). A, Prevalence of GBS serotypes presented as 
percentage (number of cases). B, Distribution of GBS serotypes by region. Serotypes included in a pentavalent vaccine are shown in blue and those not included are shown in red.
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When we limited LOGBS estimates to studies with complete 
data for days 7–89 after birth (11/33 studies), the incidence esti-
mate was 0.40 per 1000 live births (95% CI, .27–.53), higher than 
the main analysis (meta-analysis in Supplementary Figure 20). 
Including only studies with data for days 7–27 after birth (3/32 
studies), the incidence was 0.16 per 1000 live births (95% CI, 
.08–.24) (meta-analysis in Supplementary Figure 21).
When we limited estimates of the EOGBS to LOGBS ratio 
to studies considered to be less subject to bias (14 studies [22–
25, 31, 42, 52, 56, 62, 63, 73, 81]), the estimated ratio was 1.11 
(95% CI, .96–1.30) and, unlike the main analysis, was similar 
across geographic regions (meta-analysis in Supplementary 
Figure 13).
DISCUSSION
Our comprehensive review and meta-analyses represent an 
important update to the previous global invasive infant GBS 
disease burden estimates [9], and most notably include new 
data from LMICs (18 new studies from 10 LICs and LMICs). 
Infant invasive GBS disease incidence and case fatality is high 
in every world region, yet likely considerably underestimated 
in settings with limited access to care and diagnostics as <10% 
of neonates with suspected serious infection have a positive 
blood culture [139, 140]. The overall estimated incidence of 
infant GBS disease, 0.49 per 1000 live births, is slightly lower 
than the previous estimate of 0.53 per 1000 live births (95% CI, 
.41–.62) [9]. While fewer studies in this review reported IAP use 
compared to the previous review (66% vs 77.0%), more weight 
(>50%) was applied to the data from Europe and the Americas 
where IAP is in use. The reduction in overall incidence is likely 
driven by lower incidence of invasive infant GBS disease in the 
Americas (0.43/1000 live births here vs 0.67/1000 live births in 
the previous review), and Europe (0.53 vs 0.57/1000 live births). 
This difference, especially in the United States where infant 
GBS rates declined notably during the study period, reflects the 
use of more recent data in our analysis.
Similarly, the incidence of invasive infant GBS disease in 
Africa (1.12/1000 live births) was also slightly lower than pre-
viously reported, although >2 times higher than in developed 
countries (0.46/1000 live births). This is the result of broader 
incidence data from Africa, including large studies in South 
Africa [24, 42, 96] Mozambique ”(Sigaúque et al, Unpublished 
data)”, and Gambia [68] reporting a high incidence of inva-
sive GBS disease, in contrast to studies in Nigeria [28, 77] and 
Zambia [62] reporting a very low incidence. Our point estimate 
for EOGBS incidence for Africa was higher compared to that 
reported in the most recent worldwide review [9], although 
LOGBS incidence for the same region was similar in both 
reviews [9]. There are many possible reasons for the increase in 
EOGBS incidence in Africa, which could be due to true emer-
gence, increases in comorbidities such as HIV [42], or improved 
data collection to detect early disease. This high incidence is 
important in terms of total burden, as CFRs in Africa were also 
4 times higher than in developed countries (18.9% and 4.7%, 
respectively); thus the greatest burden of cases, and deaths, is 
in Africa. However, our data are limited to few African studies 
mostly in Southern and Eastern Africa.
There are other important regional differences. The inci-
dence of infant GBS disease was strikingly low in Asia at 0.31 
per 1000 live births, with the lowest incidence in Southeast 
Asia (0.21/1000 live births). This may reflect a true regional dif-
ference, which could be related to differences in lower overall 
prevalence of maternal colonization and/or lower prevalence of 
serotype III [13], which is more commonly associated with the 
most virulent clone, clonal complex 17. Some of the difference 
may also be due to incomplete case ascertainment, being in Asia 
more challenging as they have more home births than Africa. 
For the earliest-onset cases (<24 hours of birth), differences in 
access to care and rapid and high case fatality can reduce case 
ascertainment. Cerebrospinal fluid sampling is infrequently 
performed in many parts of this region and that would reduce 
the apparent incidence of LOGBS disease, which is more fre-
quently associated with meningitis. However, the lack of 
late-onset cases in this region does not fully align with those 
reasons and also suggests there may be more at play, potentially 
related to strain differences, level of natural acquired protective 
maternal antibody, or other host, environmental, or behavioral 
factors that may affect disease burden.
Difficulties in case ascertainment in LICs likely contribute to 
the higher incidences observed when the analysis was limited to 
facility-based studies, particularly in Africa. Studies in contexts 
where access to care, particularly for home deliveries, is difficult 
are likely to underestimate EOGBS disease incidence, due to the 
preponderance of cases with onset on day zero, which can be 
as high as 90% in studies with high-quality ascertainment but 
was 68% among the studies we included where this informa-
tion could be extracted. Late-onset disease is likely underesti-
mated too, due to studies that did not capture cases for the full 
7–89 days; the sensitivity analysis showed the incidence of late 
onset disease to be almost twice as high (0.40 vs 0.26) when 
only studies with data for days 7–89 were included. This may 
result in an underestimation of the burden of GBS meningitis in 
particular, a significant concern given the morbidity associated 
with this condition.
Differences in the early- to late-onset disease ratios in differ-
ent regions in the main analysis may also reflect (and reveal) 
biases in the data. Asia had the highest ratio of EOGBS disease to 
LOGBS disease, with the lowest in Africa (5.99 vs 1.02). It is pos-
sible that Asia has less LOGBS disease, consistent with the lower 
prevalence of maternal colonization with serotype III, a serotype 
commonly associated with LOGBS disease. Interestingly, when 
limiting the EOGBS:LOGBS ratio to high-quality studies, the 
estimate was similar across regions and lower than the overall 
EOGBS:LOGBS ratio. This is likely to be influenced by those 
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countries with widespread IAP as well as South Africa, which 
may have a uniquely low ratio due to the high prevalence of 
maternal HIV infection, which predisposes to late-onset disease. 
However, no study from Asia was included in this analysis.
In terms of serotypes causing invasive disease, serotype III 
accounted for over half of all disease-causing isolates followed 
by serotypes Ia, V, and II, consistent with previous work [9, 141]. 
Disease-causing serotypes were similar in prevalence across dif-
ferent regions, with some slight variations. The lowest preva-
lence of serotype III (where data were available) was found in 
South America and Southeast Asia, 2 of the regions with the 
lowest prevalence of serotype III among colonized pregnant 
women [13]. Serotype distribution was similar to that reported 
in the previous review [9], suggesting stability over time.
Our findings suggest GBS disease is an important cause of 
infant disease, despite the limitations in the data and uncer-
tainties about the low incidence in Asia. In Africa, where the 
incidence is highest, the CFR is also highest, suggesting this is 
the region where prevention strategies are most critical to intro-
duce. Existing preventive strategies using IAP are not usually 
available in low-income contexts and, with a higher number 
of home deliveries and late presentation to health facilities for 
delivery, IAP may be more difficult to implement. Maternal 
vaccination offers an alternative strategy, and the data we have 
suggest that a pentavalent conjugate vaccine (including Ia/Ib/II/
III/V) would cover almost all disease-causing serotypes (96%) 
in young infants worldwide (Table 2).
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